ERBB2 and breast carcinoma: In HER2-enriched breast cancer, statins may disrupt lipid raft structures that support the localization of HER2 receptor, inhibiting HER2-related signaling, potentiating HER2-targeted therapy (e.g., trastuzumab), and delaying resistance development [22].